project id: TCGA-THCA; case submitter id: TCGA-FY-A4B0; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.65; concentration: 0.16; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.86; rna integrity number: 8.8; age at index: 76; days to birth: -27946; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1936; age at diagnosis: 27946; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage I; ajcc pathologic t: T1a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 420.0; icd 10 code: C73; last known disease status: not reported; morphology: 8340/3; primary diagnosis: Papillary carcinoma, follicular variant; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Thyroid gland; synchronous malignancy: No; tissue or organ of origin: Thyroid gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: yes; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 72; days to sample procurement: 0; initial weight: 90.0; portion submitter id: TCGA-FY-A4B0-01A-21; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 10.0; percent tumor cells: 70.0; percent tumor nuclei: 65.0;